Discovery of YTB53, a Marine-Derived MNK-Active Anti-Acute Myeloid Leukemia Lead with Multi-Kinase Activity
Key Points
The aim is to identify and optimize YTB53 as a potential therapy for acute myeloid leukemia (AML).
Discovery of YTB53 through marine sources.
Evaluation of its anti-AML properties and kinase activity.
Plans for medicinal chemistry optimization to enhance pharmacokinetics.
YTB53 exhibits promising anti-AML activity.
Demonstrates multi-kinase activity relevant for AML treatment.
Abstract
as a promising multimechanistic lead for AML therapy, warranting further medicinal chemistry optimization to improve its pharmacokinetic properties and advance its development potential.
AI에게 질문
Like
Bookmark
Share
AI에게 질문
Like
Bookmark
Share
Discovery of YTB53, a Marine-Derived MNK-Active Anti-Acute Myeloid Leukemia Lead with Multi-Kinase Activity | Synapse